Tirzepatide Shows 22% Weight Loss in Landmark SURMOUNT-5 Trial

Eli Lilly's tirzepatide demonstrated superior weight loss compared to semaglutide in the head-to-head SURMOUNT-5 trial, with a mean reduction of 22.8% body weight.